Private Equity Firms Acquired Majority Stake in Fullscript
The deal signals continued investor interest in digital health platforms used by practitioners to manage wellness product dispensing.
Updated on Oct. 14, 2026 in Healthcare
Live Poll
Do you trust private equity firms to manage healthcare technology platforms effectively?
Altas Partners and L Catterton have agreed to acquire a majority stake in Fullscript, a platform for healthcare practitioners to recommend and dispense wellness products. The transaction involves a sponsor-to-sponsor sale, with previous majority owners HGGC and Snapdragon Capital Partners exiting their positions.
Why it matters
The transition of a specialized health-software provider between major private equity sponsors underscores the institutional scale and value assigned to digital platforms that integrate wellness product distribution into clinical workflows.
Altas Partners and L Catterton have moved to take control of Fullscript in a sponsor-to-sponsor deal, succeeding HGGC and Snapdragon Capital Partners. Financial details of the stake acquisition remain undisclosed.
The players
Fullscript
A digital platform provider that enables healthcare practitioners to recommend and dispense wellness products to patients.
Altas Partners
A private equity firm that manages large-scale capital for long-term investments in businesses.
L Catterton
A consumer-focused private equity firm with a global reach and extensive portfolio in the healthcare and retail sectors.
HGGC
A middle-market private equity firm focused on leveraged buyouts and growth equity investments.
Snapdragon Capital Partners
An investment firm that targets growth-stage companies within the consumer and health-related sectors.
The details
The transaction facilitates the transfer of ownership of Fullscript, a digital platform that automates the recommendation and dispensing of wellness products for healthcare providers. The deal, which utilized advisory support from Centerview Partners for the company and a consortium of investment banks including Evercore, Morgan Stanley, and RBC Capital Markets for the buyers, reflects the ongoing consolidation of health-tech tools that bridge clinical practice and e-commerce.
Timeline
The transaction is expected to close in the fourth quarter of 2026.
Market Landscape
This deal follows a broader industry pattern of private equity firms trading high-growth digital health assets to consolidate market share in the practitioner-led commerce space. It reinforces the role of specialized software platforms as key infrastructure for modernizing clinical product distribution.
Operators using digital dispensing platforms should monitor whether this change in sponsorship leads to significant shifts in service pricing, software feature sets, or vendor integration requirements. If you rely on such platforms, consult with your procurement team about potential long-term contract impacts during this transition.
The takeaway
The move of Fullscript between private equity sponsors highlights the ongoing investor appetite for platforms that simplify supplement and wellness dispensing. Closely monitor service-level agreement renewals and any product updates from your digital health partners as ownership changes.
What happens next
The transaction is expected to finalize in the fourth quarter of 2026.
Further reading
For more on industry shifts in digital medicine, see the latest coverage at Healthcare.
Source note: This article includes information reported by Hedgeco.
Live Poll
Do you trust private equity firms to manage healthcare technology platforms effectively?
